Core Points - ESSA Pharma Inc. has amended its Business Combination Agreement with XenoTherapeutics Inc., resulting in revised cash distributions for shareholders [1][2] - Shareholders are now expected to receive approximately $0.12 per share in cash, plus a contingent value right (CVR) that could yield up to $0.14 per share, totaling potential distributions of approximately $6.7 million depending on certain liabilities [2][3] - The special meeting for shareholders has been adjourned to October 3, 2025, to allow time for consideration of the amended agreement [4][5][6] Financial Details - The initial cash distribution to shareholders was approximately $1.69 per share, which was lower than the previously estimated $1.91 per share [2][3] - The CVR represents a right to receive additional payments based on the outcome of certain contingent liabilities, potentially increasing total shareholder returns [2] Legal and Procedural Updates - ESSA intends to apply to the Supreme Court of British Columbia to amend the interim order related to the special meeting and set new deadlines for dissent notices and court hearings [4] - Supplemental proxy materials reflecting the revised terms will be filed by ESSA in due course [7] Advisory Information - Leerink Partners is serving as the exclusive financial advisor to ESSA, with legal counsel provided by Blake, Cassels & Graydon LLP and Skadden, Arps, Slate, Meagher & Flom LLP [8]

Core Viewpoint - Elevation Oncology has entered into a definitive merger agreement with Concentra Biosciences, where Concentra will acquire Elevation for $0.36 per share in cash, along with contingent value rights [1][2] Company Overview - Elevation Oncology is focused on developing selective cancer therapies for solid tumors with significant unmet medical needs [5] Merger Details - The merger agreement includes a cash payment of $0.36 per share and a non-tradeable contingent value right, which entitles shareholders to receive 100% of net cash exceeding $26.4 million and 80% of net proceeds from the disposition of EO-1022 within five years [1] - A wholly owned subsidiary of Concentra will commence a tender offer by June 23, 2025, to acquire all outstanding shares of Elevation's common stock [3] - The merger is expected to close in July 2025, subject to conditions including the tender of a majority of shares and the availability of at least $26.4 million in cash [3]